

CV – Pharmaceutics | Biopharmaceutics | Pharmacokinetics

Amusa S. Adebayo
Assoc. Prof. of Pharmaceutics
Howard University College of Pharmacy
amusa.adebayo@howard.edu / pharmplus246@gmail.com

EDUCATION	
2017 - 2020	University of Illinois, Chicago, MS (Health Informatics)
1999 - 2001	University of Ibadan, Nigeria, PhD
1997 - 1999	Obafemi Awolowo University Ile-Ife, Nigeria, (M.B. A.)
1992 - 1995	Obafemi Awolowo University Ile-Ife, Nigeria (MSc. Pharmaceutics)
1985 - 1989	Obafemi Awolowo University Ile-Ife, Nigeria, BPharm. (1989)
Additional Training/Licensure	
2020 (Dec) – May 2021	Northwestern University, Evanston, Illinois, Cert. Data Science & Visualization
2024 (Oct) – 2025 (Sept)	Transforming Biomedical Research and Academic Faculty Through Leadership Opportunities, Training, and Mentoring (TRANSFORM) Program, Institute for Clinical Research Education, University of Pittsburgh.
Apr 15, 2014	Presenting Data and Information Course by Edward Tufte, Chicago Fairmont
Nov. 1 – 3, 2011	Introduction to Phoenix WinNonlin, Pharsight Corporation, CA at Waltham, Massachusetts
January 26 – 30, 2009	ISO 17025 Assessor Training Course, Jamaica National Agency for Accreditation
Oct. 22 – 26, 2007	PAHO/WHO Workshop on "Training in High Performance Liquid Chromatography (HPLC) and Dissolution Test in Quality Control of Antiretroviral Drugs"
March 14 – 16, 2006	ISO/IEC 17025 and Accreditation, National Quality Infrastructure Project. Ministry of Commerce, Science and Technology, Jamaica
1990 - present	Registered Pharmacist, Pharmacy Council of Nigeria # 009369. Current annual license dated July 9, 2025.

ACADEMIC EXPERIENCE	
(Nov. 2022 – date)	Howard University, Washington DC. – Assoc. Prof. Pharm. Sci.
Aug. 2021 – Nov. 2022	Larkin University, Miami, Florida – Assoc. Prof. Pharm. Sci.
2020 - 2021	University of Ilorin, Nigeria – Professor of Pharmaceutics (visiting)
2018-2019	Sullivan University, Louisville, Kentucky - Prof. Pharm. Sciences
2011-2018	Roosevelt University, Schaumburg, IL - Associate Prof. Biopharmaceutics & Pharmacokinetics
2010-2011	University of The West Indies, Trinidad & Tobago, West Indies - Senior Lecturer in Pharmaceutics
2007- 2009	University of Technology, Jamaica - Assoc. Prof. in Pharmaceutics
2002 – 2007	University of Technology, Jamaica - Lecturer in Pharmaceutics

2001-2002	Obafemi Awolowo University Ile-Ife, Nigeria - Research Fellow II
1995-2001	Obafemi Awolowo University Ile-Ife, Nigeria - Research Fellow 1
1992-1995	Obafemi Awolowo University Ile-Ife, Nigeria - Junior research fellow

ADMINISTRATIVE/LEADERSHIP EXPERIENCE	
Sept 1, 2025 - present	Interim Vice Chair, DPS, HUCOP
2007-2010	Head (Chair) School of Pharmacy and Health Sciences (SPHS), University of Technology, Jamaica
2008	Chair, Planning Committee, 1st International Scientific Symposium. Faculty of Health and Applied Science, Kingston, Jamaica, 5th June 2008. (Plenary: Prof. Peter York, IPI, Bradford, UK.)
2006-2008	Program Director, MPhil Pharmaceutics, SPHS, UTech, Jamaica
2003-2005	Program Leader (Director), Post-diploma Bachelor of Pharmacy degree program, SPHS, UTech, Jamaica.
1995-2002	Head of Drug Production section, Drug Research & Production Unit, Faculty of Pharmacy, Obafemi Awolowo University, Nigeria.
1998-2002	Secretary, Osun State Pharmacists Multipurpose Credit Union.
1992-2002	Pharmacists-in-Charge, Production Unit of the Drug Research and Production Unit (DRPU), Faculty of Pharmacy, Obafemi Awolowo University.

TEACHING EXPERIENCE & COURSES TAUGHT		
Howard University College of Pharmacy, Washington DC (Ongoing courses)		
Code	Title	PharmD/PhD
PHSC 504	Biophar & Pharmacok. Mod. (Graduate Elective) 3 credit hours. (Coordinator)	PhD
PHSC 313	Pharmaceutical Calculations II. 2 credit hours.	PharmD
PHSC 314	Pharmacokinetics. 4 credit hours	PharmD
PHSC 701	Research. 3-5 credit hours. (Mentor/Coordinator)	PhD
PHSC 429	Biopharmaceutics. 3 credit hours, March 2026.	PharmD
PHSC 801	Dissertation. 5 credit hours.(Mentor)	PhD
CLPS 026	NAPLEX/MPJE Readiness II. 0 credit hours. (Coordinator)	PharmD
PHSC 323	Pharm Calculation I. 3 credit hours.	PharmD
CLPS 027	Pharmacy NAPLEX/MPJE Readiness III.	PharmD
PHSC 336	Pharm Compounding Lab. 2 credit hours.(Coordinator)	PharmD
PHSC 313	Pharmaceutical Calculations II. 2 credit hours.	PharmD/PhD
CLPS 026	NAPLEX/MPJE Readiness II. 0 credit hours. (Coordinator)	PharmD
PHSC 323	Pharm Calculation I. 3 credit hours.	PharmD

PHSC 307	Pharmaceutics I. 4 credit hours.	PharmD/PhD
PHSC 600	Research. 3 credit hours.	PharmD
CLPS 347	Applications for Pharm Prac II. 1 credit hours. (Co-Coordinator)	PharmD
PHSC 504	Biophar & Pharmacok. Mod. 3 credit hours(Coordinator)	PhD
CLPS 027	NAPLEX/MPJE Readiness III. 0 credit hours. (Coordinator)	PharmD
PHSC 313	Pharmaceutical Calculations II. 2 credit hours.	PharmD
PHSC 307	Pharmaceutics II. 4 credit hours.	PharmD/PhD
PHSC 316	Physico-Chem Prin of Pharmacy. 2 credit hours..	PharmD
PHSC 404	Research. 3 credit hours.	PharmD
CLPS 024	NAPLEX/MPJE Readiness. 0 credit hours. (Coordinator)	PharmD
CLPS 026	NAPLEX/MPJE Readiness II. 0 credit hours. (Coordinator)	PharmD
PHSC 323	Pharm Calculation I. 2 credit hours.	PharmD
PHSC 336	Pharm Compounding Lab. 2 credit hours. (Coordinator)	PharmD
PHSC 600	Research. 1 credit hours.	PharmD
CLPS 24	NAPLEX/MPJE Readiness. 0 credit hours. (Coordinator)	PharmD
PHSC 600	Research. 1 credit hours. (Coordinator)	PharmD

New Courses Developed	
2023 - 2026	Member of the Task Force that developed the Prioritization Investment Grant Proposal (AY 2022-2023) for the Online PharmD program that was approved by the university for offering
2026	Subject Matter Expert & Instructor of Record ; developed the course plan for the Online PharmD Pharmaceutics 2 course
Spring 2026	Subject Matter Expert & Instructor of Record ; developed the course plan for the Online PharmD Pharmaceutics 2 course
Spring 2026	Subject Matter Expert & Instructor of Record ; developed the course plan for the Online PharmD Pharmaceutical Compounding course
Summer 2023	NAPLEX/MPJE Preparatory Course – Summer/Fall/Spring – Co-developer/ Co-coordinator
Spring 2024.	Biopharmaceutics & Pharmacokinetics Modeling & Simulations PG Elective (3 credit Unit) PHSC-18100. Spring 2024, PHSC-504-01 – Sole teacher/coordinator
Fall 2024	Pharmaceutical Unit Operations PG Elective. August 2024 – Present: In this course, student will gain an appreciation of the mechanistic processes and operations that manufacturing pharmacist use for converting drug substances to medicine (compounding/manufacturing) and their underlying scientific and engineering principles that could be applied and controlled for ensure end -product of the right design and performance quality. Important unit operations that will be covered include size reduction and separation, mixing, compression, and consolidation (compaction), evaporation, drying,

	centrifugation, etc. that are commonly applied in compound/manufacturing processes. Student will formulate, compound, and assess quality and stability of model formulations of select drugs among those commonly compounded or are likely to be compounded in clinical, community or hospital setting. Glossary of Unit Operations contains: Heat transfer; extraction, filtration, sieving & sieve analysis, clarification, centrifugation, diffusion, dialysis, distillation, comminution, mixing, granulation & assessment of granule properties, capsule filling, compression & tableting, container selection & packaging. Projects in selected unit operations for specific product categories may be assigned to be completed by individual or group of students to train in hands-on methods of product making or quality assessment/evaluation. (New, Coordinator)
--	--

Revised courses

August 2024 - December 2025	Revised Existing Course. 2025 Spring Pharm Compounding Lab (PHSC-336-01). The old Pharmacy Compounding course (Fall 2023 Pharm Compounding Lab (PHSC-336-01) was overhauled . A new course plan was developed together with a new, case-based Compounding Manual. The course was moved from Fall to Spring to bring it closer to when Pharmaceutics 1 and 2 theory courses were taught to P1 class. This enhanced student learning and, hopefully, would improve retention that will manifest ultimately in improved outcome in NAPLEX exam beginning in the next 2 years.
August 2024 – Present:	Revised Existing Course. 2025 Spring – Pharmacy. Pharmaceutics I (PHSC-307-1). The course plan was overhauled to remove redundancy and integrate Physicochemical Principles of Pharmacy (Spring 2024 Physico-Chem Prin of Pharmacy (PHSC-316-01) into Pharmaceutics 1 and Pharmaceutics 2. Pharmaceutics 1 focuses essentially on non-sterile products with United States Pharmacopoeia Chapter 795 while Pharmaceutics 2 focuses mainly on Sterile products prepared by Aseptic Techniques in accordance with USP 797
January 2025 – Present:	2025 Spring - Pharmacy Pharmaceutics II (PHSC-326-01). The course plan was overhauled to remove redundancy and integrate the old Physicochemical Principles of Pharmacy (Spring 2024 Physico-Chem Prin of Pharmacy (PHSC-316-01) course into Pharmaceutics 1 and Pharmaceutics 2. Pharmaceutics 2 focuses mainly on Sterile products prepared by Aseptic Techniques in accordance with USP 797 while Pharmaceutics 1 focuses essentially on non-sterile products with United States Pharmacopoeia Chapter 795.

TEACHING AT PREVIOUS INSTITUTIONS (Prior to joining Howard University)

Professional PharmD

(Larkin University College of Pharmacy) – 2021 – 2022

PH501-B1	PH501-B1 – Introduction to Pharmacy (Calculation component)
PH503-B2	PH503-B2 – Molecular Biology & Genetics (Mutation & rDNA technology, Drug Receptors & Ion Channels, & Immunity & Inflammation components)
PH504-B4	PH504-B4 – Pharmaceutics I with Extemporaneous Compounding (Co-taught)

PH506-B6	PH506-B6 – Pharmaceutics II with Aseptic Technique (Co-taught)
PH512-B1	PH512-B1 – Biopharmaceutics & Pharmacokinetics (Co-taught)
PH614-B5	PH614-B5 – Infectious Origin Disorders IV (Foundation PK Principles)
PH615-B6	PH615-B6 – Treatment of Special Populations & Critical Care (Select Pharmacy Calculations & Hepatic & Renally Impaired)
Professional PharmD (Roosevelt University College of Pharmacy, Schaumburg, IL)	
PHAR519	PHAR519 Pharmaceutical Calculations (2011 – 2018)
PHAR 561	PHAR 561 Drug Delivery Technology (Research elective) – 2014 - 2017
PHAR659	PHAR659 Pharmaceutical Unit Operations in Advanced Compounding (Research Elective) 2014 – 2017.
PHAR520	PHAR520 Pharmaceutics I (Drug Delivery & Non-sterile Compounding Laboratory) 2011 – 2018.
PHAR521	PHAR521 Pharmaceutics II (Drug Delivery & Sterile Compounding Laboratory) - 2011 – 2018.
PHAR522	PHAR522 Biopharmaceutics & Pharmacokinetics (with Computer Modeling and Simulations Laboratory) - 2011 – 2018.
PHAR573	PHAR573 Individualized Therapy and Personalized Medicine (Elective) -2014 – 2017.
PHAR 556	PHAR 556 Dispersed Systems (Elective) – 2014 – 2017.
MS Pharmaceutics & Biotechnology – University of Technology, Jamaica	
2007 - 2009	As Head of School of Pharmacy & Health Sciences, lead the development and implementation of a new PharmD program in the college of Health Science in between
2005	Developed and implemented a new MPhil (Pharmaceutics) program in the School of Pharmacy and mentored 11 graduates between 2005 and 2009.
PHA5001	PHA5001 Principles of Dosage form design and development 3 Cr
PHA5002	PHA5002 Advanced Dispersed System and Stability of Pharmaceutical Preparations 3 Cr
PHA5003	PHA5003 Pharmacometrics and Experimental Design 3 Cr (Co-taught)
PHA5004	PHA5004 Advanced Laboratory Based Research 2Cr
PHA5005	PHA5005 Advances in Technology of Solid Dosage forms 4 Cr
PHA5012	PHA5012 Modern Separation Techniques and Pharmaceutical Analysis 4 Cr (Co-taught)

RESEARCH

Notable ongoing research projects:

- 1. Active targeted delivery of niosomal combinations drugs to H. pylori Cells" (On-Going). (July 2023 - Present).**

The bug causing stomach (gastric)ulcers (Helicobacter pylori) has been implicated in gastric cancers making it a Class 1 cancer-causing bacteria according to the World Health Organization's (WHO's) classification. Unfortunately, many of the existing antibiotics are either no longer working or are losing potency against the bacteria. We propose to develop a lipid envelope (niosomes) of two drugs and attach H. pylori-specific cellular components that will enhance the drugs' uptake by the bacteria cells. By further encapsulating the niosomes formulation in hard-shell capsules that will target the drugs to the membrane of the stomach, we will be delivering the drugs passively to the stomach where it will be released and thereafter be taken up actively by the bacteria resident in the gastric cell wall. Overall, this approach will help reverse

<p>resistance to the drugs, increase potency of the drugs, and reduce toxicity of the drugs, with the ultimate goal of eradicating the H pylori, and abolishing its insidious disease causation of ulcer and cancers. Preliminary data generated to date are being used to support National Institute of Health (NIH) and/ National Scientific Foundation (NSF) grants applications.</p>
<p>2. Design of niosomes of anti-infective and anticancer agents" (2023 - Present). Design of clarithromycin and levofloxacin niosomes for combating resistant strains of bacteria is the second phase of a series of projects aimed at preparation, characterization and evaluation of drug nanoparticles for resistance mitigation in anti-infective and cancer cells. Niosomes of clarithromycin/levofloxacin are targeted at H. pylori, a pernicious and notorious cell in gastric and duodenal ulcers etiology. It has also been implicated in gastric adenocarcinoma and lymphoma, necessitating targeted delivery of anti-H. pylori and anti-cancer agents to the regions of its residence in gastrointestinal system. Preliminary data generated to date are being used to support National Institute of Health (NIH) and/ National Scientific Foundation (NSF) grants applications.</p>
<p>3. PK Modeling and Simulations using Gastroplus software (Simulations Plus, Inc.)" (On-Going). (2022 - Present). This project involves Pediatric PK Modeling/Simulations using Gastroplus PK/PD modeling and simulations software. Data generated from in vivo animal studies of niosome bioavailability are being imputed into the Gastroplus menu for characterization of the best model that describe niosomes behavior in animals. Another line of research is imputing clinical bioavailability data from adult population and concatenating it with pediatric physiologic and enzyme parameters to predict pediatric PK parameters.</p>
<p>4. Information Technology in Pharmaceutical Compounding & Pharmacy Education As of part of the commitment to developing our PharmD students in current and applicable compounding and HIT skills and knowledge, so they can serve the patients, customers and potential employers at their best on graduation. This meta analysis research is guiding PharmD students in exploring the current approaches by which pharmacy schools are incorporating health information technology into their curricula towards producing pharmacy IT-ready graduates.</p>
<p>Completed Research Projects</p>
<p>1. Active targeted delivery of niosomal combinations drugs to H. pylori Cells" (On-Going). (July 2023 - June 2024). ACS-RCIM PILOT GRANT SUPPORTED The bug causing stomach (gastric)ulcers (Helicobacter pylori) has been implicated in gastric cancers making it a Class 1 cancer-causing bacteria according to the World Health Organization's (WHO's) classification. Unfortunately, many of the existing antibiotics are either no longer working or are losing potency against the bacteria. We propose to develop a lipid envelope (niosomes) of two drugs and attach H. pylori-specific cellular components that will enhance the drugs' uptake by the bacteria cells. By further encapsulating the niosomes formulation in hard-shell capsules that will target the drugs to the membrane of the stomach, we will be delivering the drugs passively to the stomach where it will be released and thereafter be taken up actively by the bacteria resident in the gastric cell wall. Overall, this approach will help reverse</p>

<p>resistance to the drugs, increase potency of the drugs, and reduce toxicity of the drugs, with the ultimate goal of eradicating the H pylori, and abolishing its insidious disease causation of ulcer and cancers.</p>
<p>2. Sequential passive-active targeted delivery of niosomal combinations drugs for colorectal cancer treatment" (On-Going). (July 2023 - June 2024). GHUCCTS SUPPORTED</p> <p>Colorectal cancer (CRC) is one of the deadliest of malignancies, ranking second to lung cancer in males and third in females. Over 50% of colorectal cancers are diagnosed at advanced stages, when chemotherapy is usually the main treatment option. Resistance to these chemotherapeutic agents is increasing, and severe adverse effects have been reported. Currently, to improve therapeutic efficacy and minimize adverse effects, attention is focused on targeted chemotherapeutics using biomarkers on cancer cells. Progress in this area has been hindered by instability in physiologic fluids, low specificity of targeting, and off-target cellular interaction with associated dose-limiting side effects. In addition, CRC mortality is 36% higher among African American men compared to other ethnic groups which make it of particular concern to the African American population. To overcome the identified problems, we will develop targeted pegylated niosomes loaded with two cytotoxic agents (5-FU and Irinotecan) for oral delivery. The niosome surface will be coated with polyethylene glycol and functionalized with a transferrin (hTfR)-specific receptor ligand for selective targeting to transferrin which is overexpressed on colon cancer cells.</p>
<p>Prior to joining Howard University</p>
<p>3. Design and Evaluation of Dosage Form for the Circadian Rhythmic Delivery of Drugs, NIH Bridge project; Summer 2012 – Summer 2015 (Role: PI) Sponsor: NIH-Bridge and NSF-Step grants.</p>
<p>4. Compounding Practice Survey/Shelf-life dating of Suspension (Role: PI) Sponsor: UTech, Jamaica and UWI, Trinidad & Tobago.</p>
<p>5. Age-appropriate Compounding of Drug Products for Managing Heart Disease in Pediatrics at the Bustamante Children Hospital, Jamaica (06/2011 – 04/2013).</p>
<p>6. Compounding Age-Appropriate Suspensions of atenolol-enalapril-hydrochlorothiazide from commercial tablets (2014 – 2018). Sponsor: UTech Jamaica</p>
<p>7. Design and evaluation of a new fixed-dose immediate release capsule of atenolol, enalapril maleate and hydrochlorothiazide (09/2011 – 06/2014).</p>
<p>8. Design and evaluation of sustained-release high-dose metformin tablets (Role: PI) Sponsor: Roquette America, Chicago, IL. 2014 -2016.</p>

<p>SCHOLARSHIP ACTIVITIES</p> <p>https://orcid.org/0000-0002-3467-2433 (*Corresponding author; **Lead author).</p>
<p>Book Chapter & Creative Works</p> <p>Moji C. Adeyeye and Amusa Adebayo (2017). Hard Shell Capsules in Clinical Trials. In Larry L. Augsburger & Stephen W. Hoag (Eds.). Pharmaceutical Dosage Forms: Capsules. ISBN: 9781351620390</p>
<p>Dissertations/Thesis</p>

1. Application of Mobile Health Technology in Management of Patients with Chronic Kidney Diseases: Status, Challenges and Prospects
2. A study of Breadfruit and Cocoyam Starches as Excipients in Paracetamol Tablet Formulations (Ph. D. Thesis, 2001)
3. Applicability of Balanced Scorecard to Performance Measurement in the Pharmaceutical Industry (M.B.A. Thesis)
4. Effect of surfactants on In Vitro Availability of Amodiaquine from Fat-based Suppositories (M.Sc. Thesis)
5. Formulation of <i>Datura metel</i> (Linn.) Leaf powder in Suspension Dosage Form (B. Pharm degree dissertation)
Peer-Reviewed Journal Articles (* = Corresponding author, **Lead author, #Research mentor)
1. Harris, T., # Adebayo, A. S. , Bennett, D., Dawkins, G., Olugbuyi, O., Scott, C., & Chambers, B. (accepted, March 2026). Real-time Quality Assessment of Pharmacist-Compounded Age-Appropriate Captopril Oral Suspension Dosage Form. <i>Journal of Arts Science and Technology (JAST)</i> .
2. Nickania A. Pryce, # Amusa S. Adebayo , Deon A. Bennett and Eugenie Brown-Myrie (2025). Eutectic Determination of a Binary Mixture of Atenolol and Enalapril Maleate. <i>Journal of Arts Science and Technology (JAST)</i> , 17(1): 167 - 186
3. Amusa Sarafadeen Adebayo **, Kafilat Omoshalewa Agbaje, Simeon Kolawole Adesina (2025). Optimized Dual Drug-loaded Niosomes for targeted delivery to Colorectal Cancer Cells, Manuscript ID: pharmaceutics-3708224, <i>Pharmaceutics</i> , 2025, 17, 900.
4. Adeleke, A., Adebayo, A. S* , #, Agbaje, K., Olajubutu, O., & Adesina, S. K. (2025). Colorectal Cancer: Therapeutic Approaches and Their Complications. <i>Biomedicines</i> , 13(7), 1646.
5. Adebayo, A. S** , Jankie, S., Johnson, J., Pereira, L. P., Agbaje, K., & Adesina, S. K. (2025). Pharmacokinetics of Levofloxacin Entrapped in Non-Ionic Surfactant Vesicles (Niosomes) in Sprague Dawley Rats. <i>Pharmaceutics</i> , 17(2), 275.
6. Adekiya, T. A., Hudson, T., Bakare, O., Ameyaw, E. E., Adebayo, A. , Olajubutu, O., & Adesina, S. K. (2024). PSMA-targeted combination brusatol and docetaxel nanotherapeutics for the treatment of prostate cancer. <i>Biomedicine & Pharmacotherapy</i> , 177, 117125.
7. Hailemeskel, B., Daftary, M., Karodeh, Y., Rungkitwattanukul, D., Adebayo, A. , McCants, T., & Awuonda, M. (2024). Hailemeskel B*, Francis A, Daftary M, McCants T, Karodeh Y, Rungkitwattanukul R, and Adebayo A. (2024), Longitudinal Exploration of Strategies Advancing Continuing Professional Pharmacy Education in a Major University: an in-Depth Study on Impact, <i>J. General Medicine and Clinical Practice</i> , 7(2); DOI:10.31579/2639-4162/153. <i>J. General Medicine and Clinical Practice</i> , 7(2). https://doi.org/DOI:10.31579/2639-4162/153
8. Adebayo, A. S** , Agbaje, K., Adesina, S. K., & Olajubutu, O. (2023). Colorectal cancer: disease process, current treatment options, and future perspectives. <i>Pharmaceutics</i> , 15(11), 2620.
9. Adebayo, A. S** . & Jankie, S. (2023, December). H. pylori eradication for mitigating gastro-duodenal cancers: Modeling pharmacokinetics of levofloxacin niosomes in Sprague-Dawley rats. <i>In Cancer Epidemiology, Biomarkers and Prevention</i> Vol. 32, No. 12: 615.

10. Olajubutu, O., Ogundipe, O. D., Adebayo, A. , & Adesina, S. K. (2023). Drug delivery strategies for the treatment of pancreatic cancer. <i>Pharmaceutics</i> , 15(5), 1318. https://doi.org/10.3390/pharmaceutics15051318
11. Adebayo, A. S* , & Panakanti, R. (2022). Intraspecies allometric equations derived using phase 1 clinical adult pharmacokinetic parameters for pediatric dosing of lamivudine, Nevirapine, and zidovudine. <i>Journal of Applied Pharmaceutical Science</i> , 26–35. https://doi.org/10.7324/japs.2022.120804
12. Jankie, S., Johnson, J., Adebayo, A. S# , Pillai, G. K., & Pinto Pereira, L. M. (2020). Efficacy of levofloxacin loaded nonionic surfactant vesicles (NIOSOMES) in a model of pseudomonas aeruginosa infected Sprague Dawley rats. <i>Advances in Pharmacological and Pharmaceutical Sciences</i> , 2020, 1–7. https://doi.org/10.1155/2020/8815969
13. Harris, T. T., Adebayo, A. S**., Bennett, D., Olugbuyi, O. Scott, C. (2018). Extemporaneous compounding for children with coronary heart diseases in Jamaica. <i>European journal of clinical pharmacy: atención farmacéutica</i> , 20(4), 204-212.
14. Pryce, N.A., Adebayo, A.S**. , Bennett, D.A. and Brown-Myrie, E. (2017). Design and evaluation of a new fixed-dose immediate release capsule of atenolol, enalapril maleate and hydrochlorothiazide. <i>Journal of Pharmaceutical Research International</i> 20(1): 1-16.
15. Okunlola A., Adebayo A.S**. , Adeyeye M. C. (2017). Development of repaglinide microspheres using novel acetylated starches of bitter and Chinese yams as polymers. <i>International Journal of Biological Macromolecules</i> . 94, 544-553. http://dx.doi.org/10.1016/j.ijbiomac.2016.10.032
16. Jankie S., Jenelle J., Lexley P. P., Adebayo A. S**. , Gopalakrishna P. (2016) Acute toxicity of sorbitan monostearate (span 60) non-ionic surfactant vesicles (niosomes) in Sprague Dawley rats, <i>British J. Pharm. Res.</i> 14(2): 1-9. doi: 10.9734/BJPR/2016/30380
17. Okunlola A, Adebayo AS** and Adeyeye M.C. (2014) Solid State Characterization of Two Tropical Starches Modified by Pregelatinization and Acetylation: Potential as Excipients in Pharmaceutical Formulations. <i>British Journal of Pharmaceutical Research</i> , 5 (1): 2231-2919
18. Adebayo A. S**. and McFarlane N. (2014) Model-Based Bioequivalence assessment of a commercial Azithromycin Capsule against Pfizer Zithromax Tablet marketed in Jamaica. <i>Journal of Applied Pharmaceutical Science</i> Vol. 4 (10), pp. 062-068 http://www.japsonline.com
19. Jankie, Satish., Adebayo, Amusa S**. , Pillai, Gopalakrishna P. (2012) In Vitro Activities of Fluoroquinolones Entrapped in Non-ionic Surfactant Vesicles against Ciprofloxacin-Resistant Bacteria Strains. <i>Journal of Pharmaceutical Technology & Drug Research</i> http://www.hoajonline.com/journals/jptdr/content/pdf/5.pdf
20. Harvey A. C., Adebayo A. S**. , Wheatley A. O, Asemota H. N., Riley C. K. (2012) Effects of Acetylation on the Micromeritics of Yam (Dioscorea sp.) Starch Powder for Pharmaceutical Application <i>West African Journal of Pharmacy</i> (2012) 23 (2) 40 – 50
21. Anderson N., Adebayo A. S** , Smith N. (2012) Physicochemical properties of Blighia sapida (Ackee) oil extract and its potential application as emulsion base, <i>Afr. J. Pharm. and Pharmacol.</i> 6(3): 200-210 (http://www.academicjournals.org/AJPP DOI: 10.5897/AJPP11.696)

22. Adebayo, A. S* , Brown-Myrie, E and Itiola, O. A. (2008) Comparative disintegrant activities of breadfruit starch and official corn starch Powder Technology (USA), 181: 98 – 103
23. Riley, C. K., Adebayo, A. S** , Wheatley, A. O. and Asemota, H. N. (2008) The interplay between yam (<i>Dioscorea</i> sp.) starch botanic source, micromeritics and functionality in paracetamol granules for reconstitution. European Journal of Pharmaceutics & Biopharmaceutics 70: 326 – 334
24. Riley, C.K., Adebayo, A. S** , Wheatley, A. O. & Asemota, H. N. (2008) Surface properties of yam (<i>Dioscorea</i> sp.) starch powders and potential for use as binders and disintegrants in drug formulations Powder Technology 185: 280 – 285
25. Riley, C. K., Adebayo, A. S** , Wheatley, A. O. and Asemota, H. N. (2006) Fundamental and Derived Properties of Yam (<i>Dioscorea</i> Spp.) Starch Powders and Implications in Tablet and Capsule Formulation Starch/Starke (Germany) 58: 418-424.
26. Adebayo, A. S* and Akala, E. O. (2005) Kinetics model for the in vitro release of an hydrophilic drug (Amodiaquine) from fat-based Suppositories Journal of Arts, Science and Technology 2: 1 – 11.
27. Babalola, C. P., Adebayo, A. S** , Omotosho, A. & Oyeyinka, A. (2004) Comparative bioavailability study of a new quinine suppository and oral quinine in healthy volunteers Tropical Journal of Pharmaceutical Research 3 (1): 291-297
28. Adebayo, A. S* and Itiola, O. A. (2003) Effects of Breadfruit and cocoyam Starch Mucilage Binders on Disintegration and Dissolution Behaviors of Paracetamol Tablet Formulations Pharmaceutical Technology (USA) (www.pharmtech.com), March: 78 – 90.
29. Adebayo, A. S* and Itiola, O. A. Compression behavior of breadfruit and cocoyam starches and the mechanical properties of their compacts. West African Journal of Pharmacy 16 (1): 42 – 50 (2002)
30. Onyeji, C. O., Adebayo, A. S** and Babalola, C. P. (1999) Effects of absorption enhancers in chloroquine suppository formulations I: In vitro release characteristics Euro. J. Pharm. Sc. (Europe) 9: 131-136
31. Adebayo, A.S* and Itiola, O. A. (1998) Evaluation of Breadfruit and Cocoyam starches as Exo-disintegrant in a Paracetamol Tablet Formulation Pharm. Pharmacol. Commun. (London) 4: 385-389

Professional Development		
Date	Activity	Description
October 16, 2024 – October 21, 2025	Academic Leadership Training	Transforming Biomedical Research and Academic Faculty through Leadership Opportunities, Training, and Mentorship (TRANSFORM) Program. Meharry Med. College, Rutgers New Jersey Med School, Oregon Health & Sci. University, America Association of Medical Colleges, Univ. of Pittsburg
May 1, 2026	Seminar	Spring 2026 Health Leaders Forum, Research Centers in Minority Institutions Program, Washington DC, USA
April 8, 2026	Seminar	American Cancer Society (ACS) information sessions, HU Cancer Center, Washington DC
October 2, 2025	Conference attendance	2025 Leadership in Higher Education Conference, Magna Publications 2718 Dryden Drive Madison, WI 53704 800-433-

		0499, ext. 2 608-246-3590, ext. 2 support@magnapubs.com www.magnapubs.com , Philadelphia, PA, USA
April 22, 2025	Professional training	Agilent Training and Application Support Consulting for HPLC Ref ID 3005357687, Agilent Technologies (Agilent University Customer Training), Santa Clara, CA, USA
October 16 – October 18, 2025	Leadership Seminar	2024 Mid-Career Minority Faculty Leadership Seminar, Association of American Medical Colleges, AAMC Learning Center 655 K Street, Washington DC, October 16, 2024 – October 18, 2024
August 22, 2024	Seminar	Agilent’s new Strengthen Your Core seminar series!, Agilent Technologies (Agilent University Customer Training), Santa Clara, CA, USA. Rockville, MD, USA
April 11 – April 13, 2024	Seminar (Podium Presenter)	Cancer Health Equity Scientific Symposium, American Cancer Society (ACS) Thursday, April 11, 2024, Barbara Jordan Conference Center, G Street Northwest, 1330 G Street Northwest Washington, DC 20005.,
April 1 – April 2, 2024	Continuing Education Program	SuRE R16 Application Bootcamp. Two-day grantsmanship training for faculty and research administrative staff leading up to the next SuRE R16 application deadline. Monday, April 1 & Tuesday April 2, 2024 (Virtual). National Institute of General Medical Sciences, Bethesda, MD, USA
AY 2023	Continuing Education Program	CITI Research Compliance Courses, Howard University, Washington DC, USA
October 22 – 25, 2023	Conference attendance	Rapid Fire 360 Scientific, American Association for Pharmaceutical Scientists (AAPS) Annual Meeting 2024, Orange County Convention Center, Orlando, FL, USA
September 29 – October 2, 2023	Conference attendance	16th AACR Conference on The Science of Cancer Health Disparities in Racial/Ethnic Minorities and the Medically Underserved, American Association for Cancer Research (AACR), Orlando, FL
January 18, 2023	Continuing Education Program	2023 EDI Institute, American Association of Colleges of Pharmacy (AACCP)
December 2020 – May 2021	Continuing Education Program	Data Science & Visualization Bootcamp, School of Professional Studies, Northwestern University, Evanston, IL, USA

Conference Podium/Poster Presentations

1. Kymani Williams^{1*}, Amusa S. Adebayo. ICH-Guided Stability-Indicating RP-HPLC Method Validation for Quantitative Assessment of Cefiderocol Across Alternative Large Volume Parenteral Matrices
2. Kiyah Brown-Samuels, Amusa S. Adebayo Health Information Technology in Compounding Pharmacies. National Pharmaceutical Association 2025 NPhA | SNPhA Annual Convention. August 1-4, 2025. Cincinnati, OH.
3. Adebayo, Amusa S., Agbaje, K. Adesina, S. K. Biorelevant Dissolution Profiles Of An Optimized Dual-Drug Niosome For Passive Targeting To Colorectal Cancer", 2025

AACP, Annual Meeting, Pharmacy Education 2025. Chicago, IL. July 19, 2025, to July 22, 2025
4. Agbaje, K. & Adebayo, A. (T1030-07-41) A Targeted Drug Delivery System for the Treatment of Colorectal Cancer, American Association of Pharmaceutical Scientists (AAPS). AAPS 2025 PharmSCi 360, Henry B. Gonzalez Convention Center, San Antonio, TX, November 9-12, 2025.
5. K.O Agbaje and A.S Adebayo. Formulation and Optimization of a Niosomal Drug Delivery System for the Treatment of Colorectal cancer. 21st Annual Yale Virtual Bouchet Conference on Diversity and Graduate Education, Yale University, Yale Graduate School of Arts and Sciences campus, New Haven, Connecticut. April 4-5, 2025.
6. K.O Agbaje and A.S Adebayo. Formulation of a Niosomal Drug Delivery System for the Treatment of Colorectal Cancer. Armour J. Blackburn Center, Friday, Washington DC. April 25, 2025.
7. 2024 Mid-Career Minority Faculty Leadership Seminar October 16, 2024 – October 18, 2024. Association of American Medical Colleges, AAMC Learning Center 655 K Street, Washington DC.
8. Adebayo, Amusa S., Agbaje, K. Sequential passive-active targeted delivery of niosomal combination drugs for colorectal cancer treatment: Niosomes formulations & Characterization of 2 anti-CRC drugs (Oral, podium). Cancer Health Equity Scientific Symposium Thursday, April 11, 2024, Barbara Jordan Conference Center, G Street Northwest, 1330 G Street Northwest, Washington, DC.
9. Rehab A Alharbi., La'Marcus Wingate, Salome Bwayo Weaver, Edmund Essah Ameyaw, Amusa S. Adebayo. Exploring Factors Influencing Healthcare Access and Quality Among Arthritis Patients: An Analysis of the Medical Expenditure Panel Survey 2020" ISPOR Digital Conference, May 22-June 24, 2024, Poster #: 12-017.
10. Adebayo, A. S. SuRE R16 Application Bootcamp. Two-day grantsmanship training for faculty and research administrative staff leading up to the next SuRE R16 application deadline. Monday, April 1 & Tuesday April 2, 2024 (Virtual).
11. Adebayo, Amusa S., Jankie, Satish, Pinto Pereira Lexley (2023). H. pylori Eradication for Mitigating Gastro-duodenal Cancers: Modeling Pharmacokinetics of Levofloxacin Niosomes in Sprague Dawley Rats (Poster). 16th AACR Conference on The Science of Cancer Health Disparities in Racial/Ethnic Minorities and the Medically Underserved, Disney's Grand Floridian Resort, Orlando, FL. (Poster presentation).
12. Adebayo, A. S., & Jankie, S. (2023). Abstract C079: H. pylori eradication for mitigating gastro-duodenal cancers: Modeling pharmacokinetics of levofloxacin niosomes in Sprague-Dawley rats. Cancer Epidemiology, Biomarkers & Prevention, 32(12 Supplement), C079-C079.
13. Adebayo, Amusa S., Jankie, Satish. Sequential passive-active targeted delivery of niosomal combinations drugs for colorectal cancer treatment: Proposal. The American Cancer Society Center for DCCR Training Annual Meeting, Omni Atlanta Hotel at CNN Center, Atlanta, Georgia. October 11 to October 13, 2023 (Poster presentation).
14. Adebayo, Amusa S., Jankie, Satish, Pinto Pereira Lexley (2023). H. pylori Eradication for Mitigating Gastro-duodenal Cancers: Modeling Pharmacokinetics of Levofloxacin Niosomes in Sprague Dawley Rats (Poster). 16th AACR Conference on The Science of

Cancer Health Disparities in Racial/Ethnic Minorities and the Medically Underserved, Disney's Grand Floridian Resort, Orlando, FL. (Poster presentation).
15. Equity, Diversity, and Inclusion (EDI) Institute 2023, Wed 1/18/2023 10:00 AM - 5:30 PM, Virtual via AACP is inviting you to a scheduled Zoom meeting. Join Zoom Meeting https://us02web.zoom.us/j/89840709023?pwd=aW12TWxYZ3RPV21QQlgxUDIvemp5dz09 Meeting ID: 898 4070 9023 ... (Jan 18, 19 & 20, All day event)
16. SoTL Bootcamp Zoom Link - Feb 6th, Mon 2/6/2023 12:00 PM - 3:00 PM
17. https://unc.zoom.us/j/97267123025?pwd=bW9MVGc4cmFBZVh6amJFZ21lK0RkQT09
18. 2023 Simulations Plus MIDD+ Scientific Conference held Wednesday, February 15th (11 AM - 3 PM EST), and Thursday, February 16th (11 AM - 3 PM EST) conversation, making new connections for future collaborations, and more!
19. RCIM Consortium national Conference, April 12 – 14, 2023, Hilton Hotel, Baltimore, MD
20. Pfizer 3D Drug Discovery and Development Workshop, Wed 4/19/2023 1:00 PM - 5:00 PM
21. 2022 Innovation Ecosystem Summit, Tue 12/6/2022, 12:00 PM to Wed 12/7/2022, 4:30 PM Virtual via link: https://hopin.com/events/2022-innovation-ecosystem-summit-d2fc0936-fa71-4202-99d3-92235b1cc403
22. Faculty Leadership Institute Mon 12/12/2022 9:30 AM - 10:30 AM
23. Amusa S. Adebayo APhA 2022 Annual Meeting & Exposition, San Antonio, Texas. March 18 – 21, 2022. (LU APhA-ASP chapter Advisor, accompanied “Patient Counseling Competition candidate).
24. Amusa S. Adebayo. Promoting Healthy Ageing: Collaborative, Integrative and the Impact of Health Information Technology in the Management of Geriatric Population (Plenary paper). 4th Biennial Nursing & Midwifery Research Conference (Theme: Promoting Healthy Ageing Through Nursing and Midwifery Research). University of Technology, Mona, Kingston, Jamaica August 8 – 9, 2019.
25. Amusa S. Adebayo, A. S., Jankie, S. & Pillai, G. (2018). In vivo pharmacokinetics of levofloxacin Niosomes, AAPS Pharm Sci. 360, Walter E. Washington Convention Center, Washington DC, United States, November 4 - 7, 2018.
26. Pryce N., Adebayo A. S., Bennett D. A.; Brown-Myrie E. Formulation and evaluation of a fixed dose combination capsule containing atenolol, enalapril maleate and hydrochlorothiazide. AACP Annual meeting 2016 Anaheim Marriott & Anaheim Convention Center Anaheim, California.
27. Adebayo A. S. Chronotherapeutics & Chronopharmaceutics of asthma (Plenary lecture, CPE credits) - Caribbean Association of Pharmacists Annual Convention, Montego Bay, Jamaica, WI, July 29 – 31, 2016.
28. Adebayo A.S., Salamah S., Foley K, Chahil, H., Lo C. J., Carlos J., Robles T., Liza K. Design and Evaluation of Novel Theophylline Delivery System for the Circadian Rhythmic Pattern of Asthma, Caribbean Association of Pharmacists & Pharmaceutical Society of Jamaica Joint convention, July 24-31, 2016, Jamaica, WI.
29. Harris T, Adebayo A. S, Bennett D, Olugbuyi O, Scott C. Extemporaneous Compounding of Captopril for Managing Cardiac Conditions in Children at a Major

Pediatric Hospital in Jamaica. AAPS Annual Meeting & Exposition 2014. San Diego, California
30. Adebayo A.S, Panakanti R, Venkatesan N, Popescus C, Adeyeye M.C. Development of a Metformin Controlled Release Tablet and a New HPLC Assay for its Dissolution Profile Evaluation. AAPS Annual Meeting & Exposition 2014. AAPS Annual Meeting & Exposition 2014. San Diego, California.
31. Okunlola A, Adebayo A.S., Adeyeye M. C. Solid State Characterization of Two Tropical Starches Modified by Pregelatinization and Acetylation: Potential as Excipients in Pharmaceutical Formulations. AAPS Annual Meeting & Exposition 2014. San Diego, California.
32. Adebayo, A. S. & Wilson, J. Need survey of post-qualification education requirements of Caribbean Pharmacists, AACP Annual Meeting, Pharmacy Education 2013, Chicago, IL.
33. Amusa Adebayo, Fred Esseku, Anjali Joshi, Ravikiran Panakanti, Ruth Adewuya, Moji Adeyeye , Age appropriate pharmacokinetic prediction for fixed-dose combination (FDC) of lamivudine, nevirapine and zidovudine using data obtained in a phase 1 clinical trial, 2012 AAPS Annual Meeting and Exposition, October 14 – 18, McCormick Place, Chicago, Illinois.
34. Amusa Adebayo, Uday Kotreka, Ravikiran Panakanti, Ruth Adewuya, Moji Adeyeye, Simulated Ocular Bioavailability of Estradiol Based on Preclinical Data in Rabbits, 2012 AAPS Annual Meeting and Exposition, October 14 – 18, McCormick Place, Chicago, Illinois October 15, 2012.
35. Jankie S., Adebayo A. S., Gopalakrishna P., In Vitro Activities of Fluroquinolones Entrapped in Non-ionic Surfactant Vesicles Against Multi-Drug Resistant Bacteria Strains, Centennial Conference of the International Pharmaceutical Federation (FIP), Amsterdam, The Netherlands, October 3 – 8, 2012.
36. Noel McFarlane, Amusa S. Adebayo and Eugenie Brown-Myrie, Design and Evaluation of Amlodipine Besylate-Hydrochlorothiazide Immediate-release combination tablets Centennial Conference of the International Pharmaceutical Federation (FIP), Amsterdam, The Netherlands, October 3 – 8, 2012.
37. Maxwell, J; Lambert, R; Laudenschach, K; Adeyeye, M; Rasty, S; Adebayo, A; Ali, F; Potempa, L; MacKinnon, G. Highlights of Interprofessional Education at Roosevelt University College of Pharmacy (Poster), Annual AACP Meeting 14 – 18 July, 2012, Kissimmee, Florida.
38. Aderson-Foster, Naomi; Adebayo, S. Amusa and Justiz-Smith, Nilza. Emulsifying properties of Blighia sapida L. (Ackee) Oil; 2nd Conference in Innovation in Drug Delivery: From Formulation to Development through Innovative Evaluation Process, 3 -6 October, 2010, Aix-en-Provence, France pg. 163.
39. Adebayo, A. S., Aderson-Foster, N. and Justiz-Smith, N. Extraction and Characterization of the Physico-chemical Properties of Blighia sapida (Ackee) Oil and its potential application as emulsion base; 2nd Conference in Innovation in Drug Delivery: From Formulation to Development through Innovative Evaluation Process, 3 – 6 October 2010, Aix-en-Provence, France, pg. 215.

RESEARCH GRANTS		
YEAR	GRANT	OUTCOME/STATUS
2026	Biodegradable PLGA-CPP-Niosome Sustained-Targeted CAB/RPV Nanocarrier for HIV. DC CFAR Pilot Awards Selection Committee, District of Columbia Center for AIDS Research' George Washington University, Milken Institute School of Public Health. Olawode, E. (PI), Adebayo, A. S (Co-PI).	Submitted
2025	26-0403 - Surface Receptors Homing Peptides as Warhead for Targeted Delivery of Drug-Loaded Nanovesicles to Colorectal Cancer Cells. AACR-Mark Foundation Chemistry in Cancer Research Grants. \$435,000 over three years. 2026-AACR-MFCR-LOI-PGs-1. Adebayo, A. S (PI); Olawode, E. (Co-PI), Thomas, M.A. (Co-PI).	Scientific committee reviewed, Not Score; Undergoing re-submission.
2025	Non-invasive approach to CRC Treatment by intrarectal Targeted Delivery of Chemotherapies AMERICAN CANCER SOCIETY. (\$263,000) Project Start Date:10/1/2026, Project End Date: 9/30/2028. Adebayo, A. S. (PI), Olawode, E. O. (Co-I), Thomas, M. A. (Co-I)	Undergoing review
2025	Targeting Cytotoxic Drugs-Loaded Niosomes to Colorectal Cancer Cells in Tumor Colonic Microenvironment, NIH-National Institutes of Health, (\$375,000). Project Start Date:7/1/2026, Project End Date: 6/30/2028.	Not funded
2024	Grant-in-Aid - NIH LCMS (LOAN NO DL-24-0136). AGILENT TECHNOLOGIES, Model: G6135CA, SPECTROMETER MASS, S/N: SG1925P101; AGILENT TECHNOLOGIES, Model: G7112B, PUMP HPLC, S/N: DEAP00895, AGILENT TECHNOLOGIES, Model: G7129A, AUTOMATED SAMPLE PROCESSOR, S/N: DEAEQ28017; AGILENT TECHNOLOGIES, Model: G7116A, THERMOSTAT, S/N: DEAED15131; AGILENT TECHNOLOGIES, Model: G7115A, DETECTOR ARRAY (LIGHTWAVES, INFRARED), S/N: DEAC60825; HEWLETT PACKARD ENTERPRISE, Model: 4QS38UC, COMPUTER CPU (PERSONAL, MICRO), S/N: MXL9181TGP; accountable property value \$167,858.02 (Acquired by NIH 09/26/2019; released to HUCOP December 2024).	Funded
2024	October 2024 - October 2025: Adebayo, A. S. (Scholar). "Transforming Biomedical Research and Academic Faculty Through Leadership Opportunities, Training, and Mentoring (TRANSFORM) Program, Institute for Clinical Research Education, University of Pittsburgh," Sponsored by Maharry Med College; Rutgers New Jersey Med. Sch., Oregon Health & Sci. University; American Association of Medical Colleges, & University of Pittsburgh., Federal, \$10,000.00. (September 5,	Funded

	2024 - September 2025). <i>The program comprises of three parts: Leadership Skills Development, Mentorship and Leadership Project, and supports me with a \$10,000 fund that could be used for conference attendance, research article APC charges and leadership project's expenses.</i>	
2024	Cell-penetrating Peptides for Targeting Cytotoxic drugs-loaded Niosomes to Colorectal Cancer Cells in Tumor Colonic Microenvironment (R21). Amusa S. Adebayo - Principal Investigator- (PI/PD), Olawode, Emmanuel Oladayo (Co-PI), Michael Thomas (Co-Investigator), Dr. Tamaro Hudson (Co-Investigator), Simeon K. Adesina (Other Key Personnel), Graduate students (K. Agbaje). National Institute of Health (NIH Appl. ID 11234906) Application ID 1R21CA305547-01 Grant amount: \$379,415.00 over 2 years. Submitted 11/19/2024.	Administratively withdrawn dated 2024-06-05 due to changes in Government policies & NIH.
2024	Application Identifier:1612659. Application Project Title: Training and Core Skills Development of Underrepresented Minority Students in Aseptic Processing and Clean-room Operations for Pharmaceutical Research & Development Adebayo, A.S (PD/PI), Adesina, SK (Co-PI), Akala, E.O. (Co-PI). Michael A. Thomas (CI), Salome B. Weaver (CI), Mary Awuonda (CI), Earl Etienne (CI). R25 Education & Training Grant. National Institute of Allergy & Infectious Diseases (NIAID), National Institute of Health (NIH) No 1R25AI189408-01. (\$1,755,000 Over 5 years) Status: Council Reviewed (Score, 60), 01/06/2025.	Council Reviewed (Score, 60), 01/06/2025. Undergoing resubmission
2024	Amusa S. Adebayo (PI) , Nkem Nonyel (Co-PI), Yinka Laiyemo (Collaborator), Emmanuel O. Akala (Collaborator), Simeon K. Adesina (Collaborator). Development of Machine Learning Algorithm for Prevention, Early Detection, and Guidance on Treatment of Colorectal Cancer. HCAI Mid-career Reinvigoration Seed Grant Proposals (\$50,000.00) - 2023/2024	Not funded.
2024	Adebayo, A., Salome B. Weaver (Co-PI). Grant ID: 1325645 Regiospecific-active targeting of drugs to Colorectal Cancer Cells. HESI Thrive - Health and Environmental Sciences Institute. Program: THRIVE Research Grant (\$40,000). Submitted April 8, 2024.	Not funded.
2024	Adebayo, A., Agbaje, K. et al (2023). Active targeted delivery of niosomal combinations drugs to H. pylori Cells. Funding and Product/Material. Tracking #: 2023-IIR-000131 (\$50,000); Sponsor: Shionogi Company.	Not funded.
2024	Pharmacokinetics Modeling & Simulations Software. A SOFTWARE LICENSE issued by SIMULATIONS PLUS, INC., Lancaster, California 93534-7059, United States, (LICENSOR, Amusa S. Adebayo,3400 4th Street NW, Washington DC. Sponsor: SIMULATIONS PLUS, INC., California. 5 Noncommercial Licenses (Commercial rate for only the base program of GastroPlus is \$47,933.00/license X 5 licenses). Supported/active.	Funded

2023	Amusa S. Adebayo (PI) Active targeted delivery of niosomal combinations drugs to <i>H. pylori</i> Cells, Sponsor: GHUCCTS-Pilot Translational and Clinical Studies award (\$39,560.00 for 1 year, 2023-2024).	Funded
2023	Amusa S. Adebayo (PI) Sequential passive-active targeted delivery of niosomal combination drugs for colorectal cancer treatment Sponsor: Howard University Diversity in Cancer Research Pilot Grant award (\$40,000 for 1 year, 2023-2024).	Funded
2023	Amusa S. Adebayo (PI) Howard University College of Pharmacy, Research Seed Grant, 2023. Award Amount - \$ 5000.	Funded
2023	Amusa Adebayo (PI) Howard University COP BMS Grant to acquired 1260 Infinity II Quaternary Pump, maximum pressure 600bar. Includes quaternary pump with integrated 4-channel degassing unit, column, connecting capillaries, solvent cabinet, solvent bottles and CAN cable (\$39,999.73)	Funded
2023	Pharmacokinetics Modeling & Simulations Software. A SOFTWARE LICENSE issued by SIMULATIONS PLUS, INC., a California corporation with principal place of business at 42505 10th Street West, Lancaster, California 93534-7059, United States, including its divisions (such as but not limited to DILsym Services, Inc. and Cognigen Corporation), hereinafter referred to as the LICENSOR, Amusa S. Adebayo, 3400 4th Street NW, Washington DC. Sponsor: SIMULATIONS PLUS, INC., California. Noncommercial License (worth \$47,933 annually).	Funded
2017	Combination Therapy with Targeted Agents to Augment Anticancer Effects (Intramural Grant for 2016-18, S. Kurup, Tambe, A. Adebayo, P. Sakharkar, D. Majerczyk, R. Panakanti and S. Deb (\$25,000.00)	Funded
2016	Gastroplus from Simulations Plus, Inc., CA. \$12,500.00 (ongoing support with research software, activated every 6 months.	Funded
2015	Niosome encapsulation and <i>in vitro</i> antibacterial effect of Clarithromycin and Levofloxacin (Intramural research grant for, \$3000)	Funded
2015	Clinical Pharmaceutics – Integration of Science of dosage form design with the art of compounding and clinical application – Book Proposal (2015 Summer Research Grant, Office of Graduate Studies, Roosevelt university) Funded	Funded
2015	Effects of Integrating Guided Pre-exposure to Electronic Recording of Calculations & Pharmacokinetics Courses with Face-to-Face Interaction on Student Learning & Performance (Teaching Innovations grant, \$1000)	
2014	Quality, Stability and Beyond-Use Dating of Compounded Atenolol, Enalapril & Hydrochlorothiazide Combination Antihypertensive Pediatric Product, Summer 2014, \$2500.	Funded
2014	Design and Evaluation of Dosage Form for the Circadian Rhythmic Delivery of Drugs, NSF-STEP Summer 2014 (\$500)	Funded

2013/2014	Roosevelt University microgrant for assessment of student academic and demographic data as predictor of success in accelerated PharmD program (\$250)	Funded
2013	High-dose metformin tablet formulation for controlled release – contracted by Roquette America Inc. (\$5,000).	Funded
2012	Development of antiretroviral formulations for treating children with AIDS (\$1,200)	Funded
2012	Design and Evaluation of Dosage Form for the Circadian Rhythmic Delivery of Drugs, NIH Bridge project, Summer 2012, 2013 (\$2,400)	
2012	Design and Evaluation of Dosage Form for the Circadian Rhythmic Delivery of Drugs, NIH Bridge project, Summer 2012 – 2013 (\$4,800)	Funded
2010	Cost-benefit, safety, and efficacy of using prefabricated adult drug products for obtaining child's dose of medication not available for children in Trinidad and Tobago (TT\$85,000.00)	Funded
2012-2016	Gastroplus® from Simulations Plus, Inc, CA. \$62,525.00 (ongoing teaching & research software support (20 licenses, 3 months in Winter term for Biopharmaceutics/ Pharmacokinetics course teaching, 6 licenses in Summer for modeling & Simulations Research. (2012 - 2016).	Funded
2012-2013	Phoenix WinNonlin® from Pharsight Corporation (A Certara Company), CA. \$112,496 to date (ongoing teaching & research software support, 20 licenses, 3 months in Winter term for Biopharmaceutics/Pharmacokinetics course teaching, (2012).	Funded
2008	Equipment Grant by Johnson and Johnson (Canada) Ltd. to the University of Technology, Jamaica (US\$5million), response to “Pharmaceutical Labs Development Appeal Proposal” (2008).	Funded
2008	Research Award for the Development of Ackee oil as Pharmaceutical Base, Univ. of Tech., Jamaica (J\$500,000.00) Funded	Funded
2007	PAHO Sponsorship to the PAHO/WHO Workshop on "Training in High Performance Liquid Chromatography (HPLC) and Dissolution Test in Quality Control of Antiretroviral Drugs" Caribbean Regional Drug Testing Laboratory, Kingston, Jamaica Funded	Funded
2006	IDRC Research Grant to Investigate Anti-competitive practices in Pharmaceuticals Distribution in Jamaica - Joint Award to UTech and Fair-Trading Commission, Jamaica by the IDRC, Canada 2006 (Ca \$45,000.00)	Funded
2005	CARIMED Ja. LIMITED Support/travel grant to the Particulate processes in the Pharmaceutical Industry Conference, Montreal, Canada , organized by the Engineering Conference International, Brooklyn, USA (June 26-30, 2005) (US\$500.00)	Funded
2005	President’s Research Initiative Award, UTech Jamaica (JD \$100,000)	Funded
2003	Research Development Award for the development of Polysaccharides from Breadfruit (<i>Artocarpus sp.</i>). As Tablet ingredient, UTech, Jamaica, 2003 (J\$ J\$ 982,583.00)	Funded

1999	World Bank/National Universities Council (NUC) equipment grant (1999)	Funded
1998	Obafemi Awolowo University Staff Development grant to support Ph. D. degree program (1998 – 2001)	Funded
1994	Learned Conferences sponsorship to attend workshop on “Modern Separation Techniques and Benchtop Bioassays” Organized by International Program in Chemical Sciences, Uppsala University Sweden & Antimicrobial Plant Research Group of Obafemi Awolowo University, Ile-Ife, Nigeria. 24-26 January 1994.	Funded
1992	Obafemi Awolowo University Staff Development grant to support M. Sc. (Pharmaceutics) degree program (1992 – 1995) Funded	Funded

MEMBERSHIP PROFESSIONAL ORGANIZATIONS

- American Pharmacists Association (APhA, 2021)
- International Pharmaceutical Federation (FIP, Reg. #26347), the Netherlands Since Jan. 2005
- America Association of Colleges of Pharmacy (since 2011)
- America Association of Pharmaceutical Scientists (since 2012)
- International Academy of Compounding Pharmacists (since 2014)

SERVICES

Services to Universities, Colleges, and Departments

Howard University

2024 – 2025	Chair, Budget & Planning sub-committee of Senate, HU, Washington DC.
2023 – 2025	Chair, Financial Aids & Awards Committee, Howard University College of Pharmacy
2023 – 2025	Elected member, Budget & Planning sub-committee of Senate, HU, Washington DC.
2023 – date	Elected member, Library Systems Research & Resources Committee of HU Senate
Jan 2024 – Feb 2024	ACS DICR pilot grant proposal /Application reviewer for HU ACS-RCIM.
	College of Pharmacy, Howard University
August 2024 – Present	Member , Curriculum Improvement Research Committee (CIRC)
Sept. 2024 – Nov. 2025	Chair , Examination Peer-Review Task Force
September 1, 2025 – present	Interim Vice Chair , Department of Pharmaceutical Sciences
2023-2024	Member , COP Deep Dive Committee that conducted the root cause analysis of factors contributing to the poor student progression in the curriculum and low outcome in NAPLEX exams
March 2023 – August 2024	Chair , Financial Aids & Awards Committee

August 2024 – present	Member , Financial Aids & Awards Committee
Nov. 2022 – August 2023	Developer & Co-coordinator , NAPLEX Preparation Courses 1, II and II
August 2024	Coordinator , NAPLEX PREP II Course
Nov. 1, 2022 – April 2023	Member , Ad-hoc Committee on (Online PharmD) Distance Pathway Exploration at HUCOP
2025 – 2026	Member , H-Prime development Task Force, Howard University College of Pharmacy Center for Pharmaceutical Research and Drug Product Development (HUCOP-CPRDPD)
	Department of Pharmaceutical Sciences, HUCOP
Feb. 2024 – May 2023	Member, Medicinal Chemistry Faculty Search Committee
Feb 2023 – April 2023	Member, BSPS Development Committee
Larkin University	
	2021 – 2022 Member & Vice-Chair, Curriculum Evaluation & Assessment Committee, Larkin University COP (LUCOP)
	2021 – 2022 Member Curriculum Resequencing Committee, Larkin University COP (LUCOP)
	2021 - 2022 Member (Alt.), Student Progression & Professionalism Committee, LUCOP
	2021 – 2022 Promotion & 5-Year Extended Contract Committee, LUCOP
Roosevelt University, Schaumburg, Illinois	
	2018 Assessor for the Regional Compounding Competition, Chicago State University Chapter.
	2016 - 2017 Member, Faculty Issues Committee of the Senate, Roosevelt University
	2015 – 2016 Member, T-35 Grant proposal committee, Dept. Pharm Sci, RUCOP
	2014 – 2016 Graduate Study Task Force, Dept. Pharm Sci, RUCOP
	2014 - 2018 Member, Budget and Planning Committee, Roosevelt University
	2011-2017 Student Learning and Assessment Committee, Roosevelt University
	2016 - 2017 Chair of Assessment Committee, College of Pharmacy, Roosevelt University
	2014 Academic Pharmacy (APPE) rotation Preceptor, Roosevelt University College of Pharmacy (2014)
University of Technology, Jamaica, Kingston, Jamaica, West Indies	
	2006 FHAS representative on University Academic Misconduct Appeals Committee (two meetings, 2008)
2006	2007- 2007 Member, University of Technology, Jamaica Committee Reviewing the University Research Policy (September 2006 – March 2007)
2006	2007Member, University’s Appointments & Promotions Steering Committee (2006)
2006	2007 - 2008 FHAS Representative on the University’s Research Committee (2006 – 2008)
	2003 - 2006: FHAS Representative on the University Post Graduate Committee
	2004 - 2006 Member, UTech 45 th Anniversary Planning Committee
Obafemi Awolowo University, Ile-Ife, Nigeria	
	April 1992 – Aug. 2002 Pharmacist-in-charge of Conventional Drug Manufacturing
	May 2001 – Aug. 2002 Member, Science and Technology Park Development Committee

	Sept. 1995 – Aug. 2002 Faculty of Pharmacy Representative on the Board of Management of the Institute of Cultural Studies
	Sept. 1995 – June 2002 Faculty representative on the Board of Management of the Institute of Public Health

PROFESSIONAL (PEER REVIEW) SERVICES (CURRENT)	
•	Pharmaceutics
•	AAPS PharmSciTech - Reviewer
•	AAPS Pharm Research – Reviewer
•	AAPS Rapid Fire Presentations (Abstracts Reviewer)
•	Starch/Starke - Reviewer

PERIODICALS/NEWSPAPER REPORTS	
New Uses for breadfruit and dasheen starch – The Gleaner, Wednesday July 30, 2003, pg. B12.	
Health and Policy – Exploring lifestyle diseases – UTECH Feature in Outlook Magazine, Kingston, Jamaica, March 2004, pg. 32	
Research at UTECH – UTECH Communicator vol. iii, Issue 4, March 30, 2004, pg. 4.	

PROFESSIONAL ORGANIZATIONS’ ANNUAL MEETING ABSTRACTS & JOURNAL REVIEWS	
○	AAPS PharmSci360, October 22-25, 2023. Appointment as abstract screener. AAPS 2023*
○	America Association of Pharmaceutical Scientists Rapid Fire Committee (RFC), Appointment as the Track Chair, Formulation and Delivery Track, May 2023*
○	Reviewer: Dr. Ahlschwede’s dossier for promotion to the rank of Associate Professor on tenure track at the Rosalind Franklin University of Medicine and Science (April – May 2022)
○	International Journal of Pharmacy Practice*
○	USP 34 – General Chapter (1118)
○	AAPS Annual Meetings (Abstract & Rapid-fire presentation reviewer) *
○	AAPS PharmSciTech (Reviewer)*
○	AAPS Pharm Research (Reviewer)*
○	E3 Journal of Biotechnology and Pharmaceutical Research (Reviewer)
○	Starch/Starke (Reviewer)
○	The Caribbean Teaching Scholar (Editorial Board Member)
○	Drug Development & Industrial Pharmacy (Reviewer)
○	West Indian Medical Journal (Reviewer)
○	West African Journal of Pharmacy (Reviewer)
○	Journal of Pharmaceutical Technology & Drug Research (Reviewer)
○	Scientific Journals International (SJI) Saint Cloud, MN, USA – January 2008 (Reviewer)
*Current	

RECOGNITIONS AND AWARDS	
2025-2026	○ Faculty of the Year Award
2025	○ Excellence in Teaching Award, Office of the Dean, College of Pharmacy 2025.
2014	○ Biggest Heart Faculty Award, Presented by the Class of 2016, Roosevelt University College of Pharmacy (2014)
2012-2014	○ Faculty Merit Awards, Roosevelt University, Schaumburg, IL (2012/2013/2014).
2005	○ President's Research Initiative Award, University of Technology, Jamaica (2005)

ADVISING & MENTORING	
YEAR	Activity
STUDENT'S CLASS/ORGANIZATION ADVISING	
Howard university COP	
2023-Present	○ Class Advisor, Co2027 PharmD students (2023 to date).
2023 Present	○ Students Organization Advisor, National Community Pharmacy Organization (NCPA) 2023 to date.
	○ Academic advisor for 7 PharmD students
LARKIN UNIVERSITY COP	
2021 - 2022	○ APhA-ASP Chapter Advisor, (LUCOP, 2021 – 2022).
ROOSEVELT UNIVERSITY COP	
2012 - 2018	○ Muslim Students Organization, RU COP
VISITING RESEARCH FELLOWS HOSTED (JUNE 2025 – DEC. 2025)	
2025	○ Yusuf Ghazali. A visiting doctoral research student from the University of Huddersfield, UK, via the short-term Turing Research Mobility visit to the College of Pharmacy, Howard University, from June 20th to July 16th, 2025.
2025	○ Lakshmi Maharaj, a SHORT-TERM exchange visitor, a research fellow from the University of the West Indies, Trinidad & Tobago, West Indies. Research topic: <i>In vivo Evaluation of Diclofenac Sodium Loaded Poly-ε- Caprolactone Microspheres</i> (IACUC-PHARM-24-02). June 2025 to December 2025.
GRADUATE STUDENTS	
PharmD Research Mentored	
2024-2025	○ Kiyah Brown-Samuels, Amusa S. Adebayo. Health Information Technology in Compounding Pharmacies (Research project). College of Pharmacy, Howard University. 2024/25.
2024-2025	○ Taylor, Bianca R., Adebayo, A. S. (2025). The Impact of Technology-Assisted Workflow Systems on Pharmacy Practice: Advancements, Challenges, and Future Directions, 2024/25.
MPhil/PhD Graduate Mentored/mentoring	
2024 present	- Williams, K. (2025, ongoing). Stability of Reconstituted Cefiderocol in Diluents for Large Volumes Parenteral Solutions. PhD research project.
2023 present	- Adeleke, A. (2023, ongoing). Targeting colorectal cancer with surface functionalized niosomes co-encapsulating 5-FU and SN38. PhD research project. Proposal defense completed (December 2025).
2023 – 2026, Jan.	Agbaje, K. (2023, Ongoing) Ligand-targeting of combination drugs to CRC. PhD research student. Oral thesis exam January 30, 2026, Graduated May 2026.
Larkin University COP	
2021-2022	○ Foster, L., Ismail, A., & Lennard, C. Co-niosome encapsulation of drug for resistance mitigation (Research Elective), LUCOP, 2022.
Roosevelt University COP	
2014	○ Chahil, H., Lo, C. J. & Kenny, L. (NSF Bridge student) - Design and Evaluation of Dosage Form for the Circadian Rhythmic Delivery of Asthma Therapy (2014)

2014	○ Aljahmi, J & Alkhatib, M. Compounding Age-Appropriate Suspensions of enalapril, hydrochlorothiazide, and atenolol (2014)
2013	○ Foley, K., Salamah, S. & Picasso, J. (NIH Bridge candidate) Chronopharmaceutics drug delivery of theophylline (2013)
Graduate mentored at Roosevelt University	
2016	● Patel, R. (MSc. Biotech, CAS) – Research thesis - Niosome encapsulation and in vitro antibacterial effect of Clarithromycin and Levofloxacin-2 (2016)
2016	● Monika Kamburova (MSc, 2016)-1 Niosome encapsulation and in vitro antibacterial effect of Clarithromycin and Levofloxacin on select drug-resistant bacteria (Mentor: Amusa S. Adebayo)
Graduate mentored at University of Technology, Jamaica	
2017	○ Mei H. Lau (MPhil, 2017) Development of chromatographic methods for the simultaneous determination of salbutamol sulphate, bromhexine hydrochloride and etofylline in pharmaceutical preparations - University of Technology, Jamaica (Mentors: Amusa S. Adebayo Deon Bennet & Cliff K. Riley).
2014	○ Shawntae Rodney (MPhil, 2017). Modification and Physicochemical Analysis of Polymers Obtained from <i>Artocarpus altilis</i> (Breadfruit)” (Mentors: Amusa S. Adebayo & Cliff Riley)
2014	○ Abayomi, M.O. (MPhil, 2014) Extraction, Characterization and Stability Kinetics of Annatto Coloring Fractions with Potentials for Application as Pharmaceutical Colorant (Mentors: Amusa S. Adebayo, Deon Bennett, Roy Porter, Janet Shelly-Campbell).
2014	○ Nickania Pryce (MPhil, 2014) Formulation and in vitro studies of Fixed-Dose Combination antihypertensive immediate release dosage form of atenolol, enalapril maleate and hydrochlorothiazide - University of Technology, Jamaica (Mentors: Amusa S. Adebayo, Deon Bennett & Eugenie Brown-Myrie).
2014	○ Tieca T. Harris (MPhil, 2014) Assessment of the current practices involving the use of re-formulated adult drug products in managing pediatric patients with heart disease at a major pediatric hospital in Jamaica (Mentors: Amusa S. Adebayo, Deon Bennett, Oluwayomi Olugbuyi, Charmaine Scott)
2013	○ Alexia Harvey (PhD., 2013) Chemical Modification of Yam (<i>Dioscorea</i> sp.) Starches and their Potential Use in Pharmaceutical Formulations - University of the West Indies, Mona Campus, Jamaica, WI (Mentors: Helen Asemota, Andrew Wheatley, Amusa S. Adebayo)
2011	○ Satish Jankie (M. Phil.) Niosome encapsulation of Fluoroquinolones and their antibacterial activities; Converted to PhD April 2011 – University of the West Indies, St. Augustine Campus, Trinidad & Tobago, WI (Mentors: Amusa S. Adebayo & Geopalkrishna Pillai)
2011	○ Noel McFarlane (MPhil., 2011) Design and evaluation of a tablet dosage form of amlodipine besylate in combination with hydrochlorothiazide - University of Technology, Jamaica, WI (Mentors: Amusa S. Adebayo & Eugenie Brown-Myrie)
2009	○ Naomi Anderson-Foster (MPhil. 2009) Development of <i>Blighia sapida</i> (Ackee) oil as pharmaceutical base - University of Technology, Jamaica (Mentors: Amusa S. Adebayo & Justiz Nilza-Smith)
2005	○ Cliff K. Riley (PhD, 2005) Physicochemical characterization of starches from Jamaican yams (<i>Dioscorea</i> spp.) and assessment of their utilization as binders in paracetamol formulations - University of the West Indies, Mona Campus, Jamaica, WI (Mentors: Helen Asemota, Amusa Adebayo, Andrew Wheatley)

CONSULTANCY		
DATE	CLIENTE	ACTIVITY
2015 - 2016	Roquette America, Geneva, North Chicago, Illinois.	Development of High-dose (1000 mg) controlled release metformin tablet formulation
2005 – 2010	MAC's Pharmaceuticals & Cosmetic Company, Old Harbour, Jamaica	Analytical method development for some generic drug products for bioavailability and bioequivalence testing; Bioequivalence studies of Azithromycin capsules against Pfizer Zithromax.
1998 - 2001	Jolliters Industry, Lagos, Nigeria	Supervised Factory layout and water for production development project; Under the Bios Consultancy Unit of Faculty of Pharmacy, Obafemi Awolowo University, developed and secured approval by national Agency for Food & Drug Administration and Control (NAFDAC) for Jollidol (Sugar-free pediatric paracetamol syrup) and Jollimal (pediatric low-sugar chloroquine syrup) in 2001.
2005 - 2009	Fair Trading Commission (FTC), an agency of the Ministry of Commerce, Science and Technology	Expert scientist on Biopharmaceutical/bioequivalent properties of some anti-hypertensive drug products, marketed in Jamaica, a part of the "Project to Identify Anti-Competitive Threats in the Pharmaceutical Supply Chain Towards Promoting a More Competitive Distribution of Pharmaceutical Products in Jamaica (Funded (Ca\$45,000) by the Canadian International Development Research Center (IDRC), Canada.
2006 - 2009	Bureau of Standards, Jamaica	Technical Assessor for the National Quality Infrastructure Program of the Bureau of Standards, Jamaica. An ISO 17025 seminar was attended in March 2006 to train assessors and laboratory personnel for different laboratories in Jamaica.
2006 – 2008	Scientific Research Council, Jamaica	Scientific Research Council, Jamaica on the project to develop ginger oleoresin as capsule dosage form (Funding: US \$2,500.00) (2006 – 2008).

SKILLS
Languages
○ Fluency – Read, write, listen, speak
○ Yoruba - Read, write, listen, speak
Product Development Skills
○ Sterile/Non-sterile products formulation design • Products compounding/Pilot batch manufacturing • Quality assessment, Stability profiling • Good compounding/manufacturing practices • In vitro/in vivo correlation • Regulatory compliance and filing • Data analysis, interpretation, and reporting • Research & Development.
Technology Skills: <i>Software</i>
○ MS office Suite (Share point, Excel, Words, Power Point, Outlook, One note). Design of Experiment (DoE), PK modeling & simulation software (Phoenix WinNonlin®, Gastroplus®), ChemDraw, Statistical/Analytic apps (SPSS, Minitab, R, Relational Data Base), Expert System design (Exsys Corvid), OpenNLP (using Unix operating system command line); Electronic Compounding Dispensing Software (Framework Long Term Care & Framework ECM).
Technology Skills: <i>Instrumentation</i>
○ High Performance Liquid Chromatography (HPLC) for drug analysis (Shimadzu Prominence & Agilent), Flash chromatography, Separatory techniques, Differential Scanning Calorimetry (DSC, TA Instruments); X-ray Powder Diffraction (XRPD); FTIR; Particle sizer; Optical and Scanning Electron Microscopy (SEM); UV spectrophotometer; Wet chemistry (buffer preparation, titrimetric, gravimetric assays), Viscometry of liquid and semi-solid dosage forms; Manesty Betapress and AAYUSH (10-station) presses tooling and operation; Carver Hydraulic Press; Roller compactor, Manesty Fitzmill (Granulator), USP/BP Disintegration tester; USP/BP Dissolution tester (Basket & paddle apparatuses); Roche friabilator; Hardness tester; ex vivo tissue culture and in vivo animal testing.

Online Presence/Social Media
○ MyGoogle Scholar profile https://scholar.google.com/citations?hl=en
○ MyNCBI https://www.ncbi.nlm.nih.gov/myncbi/amusa.adebayo.2/bibliography/public/
○ Amusa S. Adebayo. FDA-approved drug products by dosage forms. Available at https://public.tableau.com/app/profile/amusa.s.adebayo/viz/FDA-approveddrugproductsbydosageforms/FDA-approvedDrugProducts#1
○ Amusa S. Adebayo. Github repositories of data analysis and visualization projects. Available at https://github.com/aadeba5?tab=repositories
○ Amusa S. Adebayo. Pharmaceutical Sciences Online. Resource for online students engagement (Under development). Available at https://pharmaceutical-sciences-online.teachable.com/admin-app/courses/index

I certify that the information contained in this CV is accurate

Signature _____ Date _____

PhD, MS, MSHI

*****END OF DOCUMENT*****

A

↳ back chapter
① Reviewer / Editor
— + date

①

① ↑ grants, research &
 project
 ②
 ③ P for presentation
 ④ Inty
 ⑤ ~~national~~
 ⑥ Regional / context
 —

— service ✓
— ✓
Approved
Levelling

— Volunteer Community

⑥

Honors & Awards

⑦

Skills (Tombas / etc)

⑧

Languages

⑨

centres sign